Evidence map›Paper›PMID 42210244›Full record

ArticleChinese medicine2026

Exploring the role of RCEO in macrophage-mediated modulation of pulmonary fibrosis.

Zhiguo Mao, Xiangke Lin, Xingyi Yang, Ying Liu, Chengfu Han, Shuo Tian, Yagang Song, Hui Zhao, Mingsan Miao

Abstract read
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiguo Mao *Department of Pharmacology, Henan University of Chinese Medicine, No. 156 Jinshui East Road, Zhengdong New District, Zhengzhou, 450046, Henan, China.
Xiangke Lin *Department of Pharmacology, Henan University of Chinese Medicine, No. 156 Jinshui East Road, Zhengdong New District, Zhengzhou, 450046, Henan, China.
Xingyi Yang *Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Zhengzhou, 450046, Henan, China.
Ying LiuCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Zhengzhou, 450046, Henan, China.
Chengfu HanDepartment of Pharmacology, Henan University of Chinese Medicine, No. 156 Jinshui East Road, Zhengdong New District, Zhengzhou, 450046, Henan, China.
Shuo TianDepartment of Pharmacology, Henan University of Chinese Medicine, No. 156 Jinshui East Road, Zhengdong New District, Zhengzhou, 450046, Henan, China.
Yagang SongDepartment of Pharmacology, Henan University of Chinese Medicine, No. 156 Jinshui East Road, Zhengdong New District, Zhengzhou, 450046, Henan, China. songyagang1016@163.com.
Hui ZhaoDepartment of Pharmacology, Henan University of Chinese Medicine, No. 156 Jinshui East Road, Zhengdong New District, Zhengzhou, 450046, Henan, China. zhaohui814@126.com.
Mingsan MiaoDepartment of Pharmacology, Henan University of Chinese Medicine, No. 156 Jinshui East Road, Zhengdong New District, Zhengzhou, 450046, Henan, China. miaomingsan@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary fibrosis (PF) is an interstitial lung disease with macrophage polarization playing a critical role. Previous research has demonstrated that essential oil from Radix Curcumae (RCEO) significantly ameliorates pulmonary sarcoidosis, an effect attributed to the modulation of macrophage polarization. However, the therapeutic potential of RCEO in PF and its underlying mechanisms remain to be elucidated. PURPOSE: To investigate whether RCEO ameliorates pulmonary function in PF mice by suppressing the polarization of M1 and M2 macrophages via suppressing the Pi3k/Akt/β-catenin and Tlr4/Myd88/Nf-κb signaling pathways.

methodsBioinformatics and network pharmacology approaches were employed to predict the potential therapeutic targets of RCEO for PF. The main components of RCEO and the primary constituents of RCEO deposited in lung tissue following inhalation were analyzed using GC-MS. PF models were established both in vivo and in vitro using bleomycin. Changes in pulmonary function were assessed by whole-body plethysmography. HE staining and Masson staining were used to observe histopathological alterations and fibrosis progression in lung tissues. ELISA was performed to measure changes in fibrosis-related mediators in blood. Flow cytometry was utilized to investigate macrophage polarization and apoptosis levels in lung tissues. Immunofluorescence analysis was applied to quantify the expression and distribution of Tlr4 and Pi3k, as well as their fluorescence co-localization with macrophages, in lung tissues. PCR and WB were conducted to evaluate changes in mRNA expression levels and protein abundance associated with the Tlr4/Myd88/Nf-κb and Pi3k/Akt/β-catenin signaling pathways in lung tissues.

resultsBioinformatics and Network Pharmacology analyses predicted that the therapeutic effect of RCEO on PF is associated with the modulation of macrophage differentiation via the Tlr4/Myd88/Nf-κb pathway and the Pi3k/Akt/β-catenin signaling pathway. In a PF mouse model, RCEO significantly alleviated pathological alterations and collagen deposition in lung tissues and improved pulmonary function. Results from both in vivo and in vitro flow cytometry demonstrated that RCEO concurrently suppressed the differentiation of macrophages into both M1 and M2 phenotypes, promoted apoptosis in 3T3 cells while inhibiting apoptosis in MLE-12 cells, and reduced the levels of profibrotic mediators. Further PCR and Western blot analyses indicated that RCEO modulates macrophage polarization and extracellular matrix expression by inhibiting the Tlr4/Myd88/Nf-κb and Pi3k/Akt/β-catenin signaling pathways. Immunofluorescence assays revealed that RCEO effectively downregulated the expression of Tlr4 and Pi3k in macrophages, thereby exerting a protective effect against pulmonary fibrosis.

conclusionRCEO ameliorates PF by suppressing both M1 and M2 polarization of macrophages via inhibition of the Pi3k/Akt/β-catenin and Tlr4/Myd88/Nf-κb signaling pathways. This leads to reduced release of pro-inflammatory and pro-fibrotic cytokines, decreased extracellular matrix (ECM) deposition, and overall attenuation of fibrotic progression.

Indexed as

MacrophagesPFPi3k/Akt/β-catenin pathwayRCEOTlr4/Myd88/Nf-κb pathway

Identifiers

PMID42210244
PMCPMC13220479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.